For much of the past two years, positive commentary across pharma services centered on a market showing signs of stabilization. This stabilization narrative was driven by improving customer dynamics, healthier pipelines and more constructive funding conditions. The latest results indicate that these signals are beginning to translate into measurable activity.

Because reported revenue typically lags customer engagement, proposal submission, award, contracting and study startup, the improving leading indicators suggest that the market is moving beyond merely finding a bottom. However, we are already seeing signs of early revenue acceleration compared to prior periods across Lincoln’s Private Market Pharma Services Index (LPMPSI) which enjoyed its highest level of sequential revenue growth in Q2 2026 since the start of 2024. It’s become more evident that sponsors are increasingly committing capital, advancing programs and selecting outsourcing partners.

The recovery is not occurring uniformly across the pharma services ecosystem, consistent with our K-shaped thesis. The clearest momentum is currently visible in clinical development after a prolonged period of pressure, where companies reported stronger RFP activity, healthy bookings, stable-to-improving cancellation rates and improved visibility into future revenue.

The benefit extends beyond traditional CROs. As programs move deeper into development, spending expands across site networks, biometrics providers, central laboratories, patient recruitment businesses, clinical technology vendors, specialty consultants and other service providers positioned around trial execution. The LPMPSI, which represents a broad basket of private pharma services companies, further supports this view based on EBITDA growth continuing to accelerate sequentially after multiple periods of contraction.

For private equity-backed platforms, the opportunity is to demonstrate that exposure to clinical development is not merely cyclical. The strongest businesses will combine an improving end market with defensible positioning in a specific, mission-critical component of the development process.

Smaller and emerging sponsors generally maintain less internal infrastructure than large pharmaceutical companies. When funded programs move forward, these customers often require more comprehensive external support across clinical operations, regulatory, data, chemistry manufacturing and controls and commercialization planning, which creates an attractive multiplier effect for differentiated outsourced providers.

Lincoln’s experts continue to believe that the recovery is exhibiting sustained selectivity. Capital is not flowing equally to every sponsor or asset, but that selectivity may support healthier service-provider economics. Better-capitalized programs with compelling science and visible milestones are more likely to advance, remain funded through execution and support broader project scopes. Key implications for pharma services companies are to:

• Evaluate biotech exposure based on funding quality, asset maturity and therapeutic focus, not customer size alone
• Differentiate between project activity and durable customer lifetime value
• Prioritize services that become more critical as programs advance through development

A healthier end market will not lift all pharma services businesses equally. Even among the largest providers, revenue growth, bookings performance and margin trajectories vary considerably. Some companies are already generating strong organic growth, while others are showing better bookings and operational performance before returning to top-line growth.

This dispersion supports the view that the next cycle will be defined by shifts in market share as much as end market expansion. Companies on the upper branch of the K are likely to combine scientific or therapeutic differentiation, direct customer relationships, strong commercial execution, mission-critical positioning and technology-enabled delivery.

Conversely, undifferentiated businesses, transactional models, lower quality customer bases and platforms with weak execution may not participate fully in the recovery. For PE investors, subsector exposure alone is insufficient; the more important diligence question is whether the company is structurally positioned to win as budgetary and funding environments improve materially.

Private equity diligence lens

Improving market activity should support revenue growth, but reported figures may remain difficult to interpret. Clinical development-focused services frequently incur significant pass-through expenses associated with investigators, sites, travel, laboratories and other third-party costs. These expenses can increase reported revenue and bookings while reducing reported margin percentages, without materially changing the underlying economics of the service provider.

Recent earnings demonstrated this dynamic more clearly as several companies reported stronger revenue and bookings alongside pressure from elevated pass-through mix, while others expanded EBITDA margins despite flat or declining revenue through cost actions, improved utilization and more favorable project mix. Favorable project mix can be one of the clearest signals of differentiation, but it can also mask a temporary tailwind. This dynamic is also becoming evident across private pharma services companies, with operating performance emerging as the primary driver of recent changes in the LPMPSI.

In Lincoln’s view, it is still too early to assign winners and losers in the face of AI adoption and there are valid points on both the bull and bear cases. What is clear is that pharma services companies need to be proactive in how they will benefit from, or pivot, in the face of AI evolution in the sector.

For PE-backed platforms, a generic AI strategy will have limited value. The greatest value will accrue to businesses that combine technology with scientific expertise, proprietary information and control of a mission-critical workflow (i.e. continuing to derive value from a human-in-the-loop model). Lincoln’s team expects the M&A market to favor assets that can demonstrate measurable improvement in customer outcomes, productivity or win rates.

The latest data appears to point to the sector moving more decisively into recovery mode, but as noted previously, it has been subject to false starts in the past. Potential risks to recovery include bookings volatility, EBP funding contraction, AI implications and increasing global competition from China. However, it appears that the predominantly positive data emerging on both the public and private pharma services landscape outweighs the downside risks.

The latest public company results support a constructive outlook for pharma services, further validated by our LPMPSI data from the most recent quarter. The clinical development market appears to have moved beyond stabilization, biotechnology activity is improving and leading indicators point toward stronger growth over the coming quarters.

However, the recovery should not be interpreted as an all-clear for the entire sector. The next phase is likely to create greater separation between companies rather than less. End market improvement will benefit differentiated platforms, but it will also expose weak commercial organizations, limited customer relevance and underdeveloped operating infrastructure.

For investors, the priority should be identifying businesses capable of converting the market recovery into sustainable organic growth, market share gains, margin expansion, customer diversification and enhanced exit optionality. For management teams, the environment presents an opportunity to move from defense to offense through targeted investments in business development, specialized talent, technology and M&A.

This latest data will also have an impact on the sector’s valuation and investors’ views of it, and not just within CROs specifically but in the broader pharma services landscape, as well as on deal flow.

• Stronger public market sentiment and improved operating environments can support private market confidence and activity.
• Clarity, stability and improving visibility can help unlock the bid / ask spread that may have existed in previous years.
• Buyers are no longer simply looking for exposure to the recovery but are placing premiums on platforms that convert the recovery into durable organic growth and market share capture before repricing is complete.

This analysis serves as a continuation of an ongoing series, in which Lincoln’s experts will further explore how investors can evaluate opportunities across the pharma services landscape. Future installments will dive deeper into the team’s framework for assessing subsector dynamics, identifying relative winners and losers and underwriting investments through the next stage of the cycle.